Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
Stefan Kubicka
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche; Sanofi
Richard Greil
No relevant relationships to disclose
Thierry André
Consultant or Advisory Role - Amgen; Roche
Honoraria - Baxter ; Merck; Sanofi
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Roche
Javier Sastre
Honoraria - Roche
Research Funding - Roche
Eric Van Cutsem
Research Funding - Roche
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Roche
Expert Testimony - Amgen
Pia J. Osterlund
Consultant or Advisory Role - Roche
Honoraria - Roche
Priti Hegde
Employment or Leadership Position - Genentech
Stock Ownership - Genentech; Roche
Martina A. Sersch
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Stuart Osborne
Employment or Leadership Position - Roche
Frank Hermann
Employment or Leadership Position - Roche
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Roche